In a multicenter, non-comparative Phase 2 trial involving 58 patients with platinum- and cetuximab-refractory R/M HNSCC, patients were assigned to receive either ficlatuzumab (an anti-HGF IgG1) alone or in combination with cetuximab. Here, HGF is linked to head and neck squamous cell carcinoma.